Japanese pharmaceutical company Astellas Pharma Inc announced on Tuesday that VEOZAH (fezolinetant), its first-in-class, targeted, non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, will be featured in six Astellas-sponsored poster presentations during The Menopause Society 2025 Annual Meeting in Orlando, Florida, on 21-25 October.

VMS, also known as hot flashes and/or night sweats, are common symptoms of menopause.

The company says that the presentations, which feature three Late Breaking Abstracts, will include two preliminary analyses from the OPTION-VMS study. These analyses evaluate, in a real-world setting, both the changes in the impact VMS among women beginning non-hormonal therapy (non-HT) for VMS and the effects on work productivity for women initiating non-HT to manage these symptoms.

OPTION-VMS is an ongoing Phase IV, longitudinal, observational, study on women aged 40-75 years with confirmed menopausal VMS who were prescribed non-HT for the treatment of VMS by their healthcare provider in a real-world setting. The primary objective of the study is to evaluate the change in VMS bother in women; additional outcomes include sleep quality, menopause-related quality of life, sexual health, mood and work productivity. A total of 998 women were enrolled at 50 sites in the US.

VEOZAH (fezolinetant) is a nonhormonal neurokinin 3 (NK3) receptor antagonist indicated in the United States for the treatment of moderate to severe vasomotor symptoms (hot flashes and night sweats) due to menopause.